

ATTACHMENT B



EV 698125511 US



UNITED STATES POSTAL SERVICE®

Customer Copy

Label 11-F, April 2004

Post Office To Addressee

ORIGIN (POST OFFICE)				DELIVERY (POST OFFICE)			
PO ZIP Code		Day of Delivery		Delivery Attempt		Time	
\$9.72		11		No. Day		<input type="checkbox"/> AM <input type="checkbox"/> PM	
Date Accepted		Scheduled Date of Delivery		Delivery Attempt		Time	
11/11/05		11/11/05		No. Day		<input type="checkbox"/> AM <input type="checkbox"/> PM	
Month Day Year		Month Day Year		No. Day		<input type="checkbox"/> AM <input type="checkbox"/> PM	
Time Accepted		Scheduled Time of Delivery		Delivery Date		Time	
11:00 AM		11:00 AM		No. Day		<input type="checkbox"/> AM <input type="checkbox"/> PM	
Military		Total Postage & Fees		<input type="checkbox"/> WAIVER OF SIGNATURE (Domestic Mail Only) Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.			
Post Office or Weight		Insurance Fee		<input type="checkbox"/> NO DELIVERY <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday			
11 lbs		\$1.00		Customer Signature			
Post Office Country Code		Assurance Fee/Initials					
11		11/11/05					

CUSTOMER USE ONLY	
METHOD OF PAYMENT: A 14 1030	
Express Mail Corporate Acct. No.	
FROM: (PLEASE PRINT)	TO: (PLEASE PRINT)
201 S MAIN ST STE 1100	COMMISSIONER FOR PATENTS
1 STON KENDRA	P.O. BOX 1450
SALT LAKE CITY UT 84111-4909	ALEXANDRIA, VA 22313-1450
Booster No. 50821/5 MSB	

FOR PICKUP OR TRACKING: Visit www.usps.com or Call 1-800-222-1811

THE UNITED STATES PATENT AND TRADEMARK
OFFICE: PLEASE STAMP AND RETURN. THANK
YOU.

Submitted: Amendment and Response (11 pgs.);
Amendment Transmittal Letter (1 pg.); Certificate of
Mailing by Express Mail Label EV698125511US;
Postcard

Applicant: Shcherbakova et al.
Serial No.: 11/531,161
Filed: April 12, 2005
Title: QUINAZOLINONE COMPOUNDS AS
CALCILYTICS
Examiner: Tamthom Ngo Truong
Mailed: March 15, 2007

Docket No.: 50821/5



CERTIFICATE OF MAILING / "EXPRESS MAIL" (37 CFR 1.16,

Applicant(s): Shcherbakova et al.

Docket No.

50821/5

Application No.

11/531,161

Filing Date

April 12, 2005

Examiner

Tamthom Ngo Truong

Customer No.

32642

Group Art Unit

1624

Invention: QUINAZOLINONE COMPOUNDS AS CALCILYTICS

I hereby certify that the following correspondence:

Amendment and Response to Office Action (including the items listed below)


(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

MAR. 15, 2007
(Date)

Kevin B. Laurence

(Typed or Printed Name of Person Mailing Correspondence)


(Signature of Person Mailing Correspondence)

EV698125511US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

Transmitted: Amendment and Response to Office Action (11 pgs.)
Amendment Transmittal Letter (1 pg.)
Certificate of Mailing by "Express Mail" Label No. EV698125511US
Postcard

AMENDMENT TRANSmittal LETTER (Large Entity)

Applicant(s): Shcherbakova et al.

Docket No.

50821/5

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
11/531,161	April 12, 2005	Tamthom Ngo Truong	32642	1624	4723

Invention: QUINAZOLINONE COMPOUNDS AS CALCILYTICS

COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	18 -	20 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- ☒ No additional fee is required for amendment.
- ☐ Please charge Deposit Account No. _____ in the amount of _____
- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 50-2375
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☐ Payment by credit card. Form PTO-2038.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Kevin B. Laurence
Signature

Dated: MAR. 15, 2007

Kevin B. Laurence
Registration No. 38,219
Stoel Rives LLP
One Utah Center
201 South Main Street, Suite 1100
Salt Lake City, UT 84111
Telephone: 801-578-6932
Facsimile: 801-578-6999

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 11/531,161 Confirmation No. 4723
Applicant : Shcherbakova et al.
Title : QUINAZOLINONE COMPOUNDS AS CALCILYTICS
Filed : April 12, 2005
TC/A.U. : 1624
Examiner : Tamthom Ngo Truong
Customer No. : 32642

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO OFFICE ACTION

Dear Sir:

In response to the Office Action of January 16, 2007, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.


Remarks/Arguments begin on page 8 of this paper.

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim1 (currently amended) A compound having the chemical formula:



wherein:

R¹, R² and R³ is each independently chosen from: H, halogen, CN, CF₃, OCF₃, lower alkyl, lower alkoxy, NH-acetyl, NH-lower alkyl, NH-alkylaryl, N(lower alkyl)₂, C(O)OH, C(O)O-lower alkyl, C(O)NH-lower alkyl, C(O)N(lower alkyl)₂, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)₂, and OP(O)(OH)₂;

R⁴ is chosen from: H, halogen, CN, CF₃, OCF₃, lower alkyl, lower alkoxy, NH-acetyl, NH-lower alkyl, NH-alkylaryl, N(lower alkyl)₂, C(O)OH, C(O)O-lower alkyl, C(O)NH-lower alkyl, C(O)N(lower alkyl)₂, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)₂, and OP(O)(OH)₂;

X¹ is selected from one of C and N, such that when X¹ is N, then R⁴ is absent;

R⁵ is chosen from: H, a thienyl, styryl, pyridyl and phenyl group, wherein the thienyl, styryl, pyridyl and phenyl group is optionally substituted with 1 to 3 substituents chosen from: H, halogen, CN, CF₃, OCF₃, lower alkyl, NH-alkylaryl, N(lower alkyl)₂, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-NH-lower alkyl, OC(O)-lower alkyl-N(lower alkyl)₂, and OP(O)(OH)₂;

R^6 comprises $-(CH_2)_n-X^2-R^7$ wherein n is 1, ~~[[or]]~~ 2 or 3, X^2 is O, C(O), CH(OH), ~~lower alkyl~~ or a single bond, and

R^7 is chosen from a pyridyl and a phenyl group, wherein R^7 is optionally substituted with 1 to 3 substituents chosen from: H, halogen, CN, OCF_3 , unsubstituted lower alkyl, NH-alkylaryl, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)₂, and OP(O)(OH)₂;

or a pharmaceutically acceptable salt or complex thereof;

wherein the compound has a Calcium Receptor Inhibitor Assay IC_{50} value of no greater than 30 μ M ~~or lower~~.

Claim 2 (original) A compound according to claim 1, wherein R^1 , R^2 , R^3 , and R^4 are independently selected from one of hydrogen, halogen, lower alkyl, OH and OP(O)(OH)₂.

Claim 3 (original) A compound according to claim 2, wherein said halogen is selected from one of fluorine and chlorine.

Claim 4 (original) A compound according to claim 2, wherein lower alkyl is methyl.

Claim 5 (original) A compound according to claim 2 wherein, R^1 is selected from one of hydrogen and methyl.

Claim 6 (original) A compound according to claim 2, wherein R^2 is selected from one of hydrogen, fluorine, chlorine, hydroxy, and methyl.

Claim 7 (original) A compound according to claim 2, wherein R^3 is selected from one of hydrogen and chlorine.

Claim 8 (original) A compound according to claim 2, wherein R^4 is selected from one of hydrogen, hydroxy, and methyl.

Claim 9 (original) A compound according to claim 1, wherein X^1 is carbon.

Claim 10 (original) A compound according to claim 1, wherein R^5 is phenyl optionally substituted with 1 or 2 hydroxy.

Claim 11 (original) A compound according to claim 1, wherein R^6 further comprises the group $-(CH_2)_n-X^2-R^7$;

wherein n is 1 or 2;

X^2 is a single bond, and

R^7 is phenyl optionally substituted with 1 or 2 halogens.

Claim 12 (original) A compound according to claim 11, wherein n is 2 and said halogens are selected from one of fluorine and chlorine.

Claim 13 (original) A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable diluent or excipient.

Claim 14 (previously presented) A method of treating a disease or disorder characterized by abnormal bone or mineral homeostasis chosen from: osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis, comprising the administration to a subject in need of treatment thereof an effective amount of a compound according to claim 1.

Claim 15 (cancelled)

Claim 16 (original) A method according to claim 14, wherein the bone or mineral disease or disorder is osteoporosis.

Claim 17 (previously presented) A method of increasing serum parathyroid hormone levels in mammals for treatment of a disease or disorder chosen from: osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis, which comprises the administration to a subject which may be benefited thereby an effective amount of a compound according to claim 1 sufficient to increase serum parathyroid hormone levels.

Claim 18 (original) A method for preparing 2,3,5,6,7,8-substituted 3*H*-quinazolin-4-ones by reacting 2,4,5,6,7,8-substituted benzo[d][1,3]oxazin-4-ones with primary amines under microwave irradiation conditions.

Claim 19 (previously presented) A compound selected from one of:

- 2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
- 2-(2,5-dihydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
- 2-(3-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
- 2-(2-hydroxy-phenyl)-3-(2-phenoxy-ethyl)-3*H*-quinazolin-4-one;
- 3-[2-(4-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 3-[2-(3-chloro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 3-[2-(2-chloro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 2-(2-hydroxy-phenyl)-3-[2-(2-methoxy-phenyl)-ethyl]-3*H*-quinazolin-4-one;
- 2-(2-hydroxy-phenyl)-3-(2-*p*-tolyl-ethyl)-3*H*-quinazolin-4-one;
- 2-(2-hydroxy-phenyl)-6-methyl-3-phenethyl-3*H*-quinazolin-4-one;
- 6-fluoro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;

6-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
2-(2-hydroxy-phenyl)-3-phenethyl-5-phenethylamino-3*H*-quinazolin-4-one;
2-(2-hydroxy-phenyl)-5-methyl-3-phenethyl-3*H*-quinazolin-4-one;
7-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
2-(2-hydroxy-phenyl)-8-methyl-3-phenethyl-3*H*-quinazolin-4-one;
6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
6-fluoro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
7-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-5-methyl-3*H*-quinazolin-4-one;
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-5-methyl-3*H*-quinazolin-4-one;
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methyl-3*H*-quinazolin-4-one;
3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methyl-3*H*-quinazolin-4-one;
6-chloro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
6-chloro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methoxy-3*H*-quinazolin-4-one;
3-[2-(3-fluoro-phenyl)-ethyl]-6-hydroxy-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
acetic acid 2-{6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-quinazolin-2-yl}-
phenyl ester;
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-8-methoxy-3*H*-quinazolin-4-one;
isobutyric acid 2-{6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-quinazolin-2-
yl}-phenyl ester;
sodium salt of 6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-
4-one;
8-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
7-chloro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
7-chloro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
2-(2-hydroxy-phenyl)-3-(2-pyridin-3-yl-ethyl)-3*H*-quinazolin-4-one;
6-fluoro-2-(2-hydroxy-phenyl)-3-(2-pyridin-3-yl-ethyl)-3*H*-quinazolin-4-one;
2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-pyrido[2,3-*d*]pyrimidin-4-one;

3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-pyrido[2,3-*d*]pyrimidin-4-one;
3-(1,1-dimethyl-3-phenyl-propyl)-6-fluoro-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
methylamino-acetic acid 2-{6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-
quinazolin-2-yl}-phenyl ester hydrochloride;
6-fluoro-2-(2-hydroxy-phenyl)-3-(2-phenyl-propyl)-3*H*-quinazolin-4-one;
6-fluoro-2-(2-hydroxy-phenyl)-3-(*R*-2-phenyl-propyl)-3*H*-quinazolin-4-one;
6-fluoro-2-(2-hydroxy-phenyl)-3-(*S*-2-phenyl-propyl)-3*H*-quinazolin-4-one; and
6-fluoro-2-(2-hydroxy-phenyl)-3-(3-phenyl-propyl)-3*H*-quinazolin-4-one
or a pharmaceutically acceptable salt or complex thereof.

REMARKS/ARGUMENTS

This Amendment is submitted in response to the Office Action mailed January 16, 2007. At that time claims 1-14 and 16-19 were pending in the application. In the Office Action, the Examiner withdrew the previous rejection under 35 U.S.C. §112, ¶¶ 1 and 2. The Examiner also found claim 19 to be allowable. However, the Examiner rejected claims 1-14 and 16-19 under 35 U.S.C. §112 ¶ 2 as being indefinite. Additionally, the Examiner rejected claims 1-3, 5-9 and 13 under 35 U.S.C. §102(b) as being anticipated by U.S. Patent No. 4,710,502 issued to Wright, Jr. et al. (hereinafter "Wright, Jr.").

By this Amendment, claim 1 has been amended. Accordingly, claims 1-14 and 16-19 are presented for reconsideration by the Examiner.

REJECTION OF CLAIMS 1-14 and 16-19 UNDER 35 U.S.C. §112, ¶ 2

In the Office Action, the Examiner rejected claims 1-14 and 16-19 under 35 U.S.C. §112 ¶ 2 as being indefinite. See Office Action, page 2. The Applicants respectfully traverse this rejection.

The Examiner rejected claims 1-14 and 16-19 because of the element "the compound has a Calcium Receptor Inhibitor Assay IC₅₀ value of 30 µM or lower." Applicants initially note that claim 19 does not depend from claim 1 and should not be included in the rejection under §112. By this Amendment, claim 1 was amended to recite "the compound has a Calcium Receptor Inhibitor Assay IC₅₀ value of no greater than 30 µM." Exemplary support for this amendment can be found in the Present Application, page 66, lines 9-13. Therefore, no new matter has been added.

The Examiner has presented essentially three reasons why the element is allegedly indefinite. First, the Examiner argues that the original phrase "or lower" did not have definite metes and bounds because it technically includes an IC₅₀ value of zero. See Office Action, page 2. Claim 1 was amended to recite an "IC₅₀ value of no greater than 30 µM," thus avoiding the Examiner's concern that the claim covers IC₅₀ values of zero.

Second, the Examiner argues, “[i]t is not clear what assay conditions are needed to obtain such an IC₅₀ value. Thus, various factors could yield the same IC₅₀ value for different set[s] of compounds.” See Office Action, pages 2-3. As pointed out in the Amendment dated December 14, 2006, there is only one assay disclosed in the Present Application, and the conditions and procedure described is the assay are to be used to obtain the IC₅₀ value recited in the claims. The assay used to determine the IC₅₀ value for a claimed compound is clearly set forth on page 64, line 27 to page 66, line 13 and is titled “Calcium Receptor Inhibitor Assay.” One having skill in the art would be able to routinely perform the assay using the procedure described to determine the IC₅₀ value as claimed. Therefore, it is clear what assay conditions are needed to obtain the IC₅₀ value recited in claim 1, and the element meets the requirements of 35 U.S.C. §112, second paragraph.

Third, the Examiner argues that the element provides functional language and does not “define any structural attributes.” See Office Action, page 3. According to MPEP §2173.05(g), “There is nothing inherently wrong with defining some part of an invention in functional terms. Functional language does not, in and of itself, render a claim improper” (*citing In re Swinehart*, 439 F.2d 210 (CCPA 1971)). “A functional limitation is often used in association with an element, ingredient, or step of a process to define a particular capability or purpose that is served by the recited element, ingredient or step.” MPEP §2173.05(g). In the present case, the recitation of “the compound has a Calcium Receptor Inhibitor Assay IC₅₀ value of no greater than 30 μM” is used in association with the claimed structure to “define a particular capability...that is served by the recited [structure].”

Not only is this consonant with MPEP §2173.05(g), but it follows the direction provided in *In re Barr*, 444 F.2d 588, 595 (CCPA 1971), which states:

The real issue in any such case [of determining definiteness] is not whether the recital is ‘functional’ or ‘negative,’ but whether the recital sets definite boundaries on the patent protection sought – that is, whether

those skilled in the relevant art can determine what the claim does or does not read on.

Judged by this standard, it is clear that the element of the claimed compound having an "IC₅₀ value of no greater than 30 μ M" complies with the second paragraph of §112 because, as described above, the specification provides a clear assay providing details necessary for one skilled in the art to determine whether or not the claim reads on a given compound. Therefore, the element meets the requirements of 35 U.S.C. §112, second paragraph. Withdrawal of this rejection is respectfully requested.

REJECTION OF CLAIMS 1-3, 5-9 and 13 UNDER 35 U.S.C. §102(b)

Claims 1-3, 5-9 and 13 were rejected under 35 U.S.C. §102(b) as being anticipated by Wright, Jr. See Office Action, page 3. Applicants respectfully traverse this rejection.

It is well settled that a claim is anticipated under 35 U.S.C. § 102(b) only if "each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference." MPEP §2131, citing *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987). "The identical invention must be shown in as complete detail as is contained in the ... claim." MPEP §2131, citing *Richardson v. Suzuki Motor Co.*, 868 F.2d 1226, 1236, 9 USPQ2d 1913, 1920 (Fed. Cir. 1989).

As a result of this paper, claim 1 was amended so that n is 1, 2 or 3 and X² does not include lower alkyl. Exemplary support for this amendment can be found on page 39 of the Present Application, compound 64, demonstrating a compound wherein n is 3. Therefore, no new matter has been added. Claims 1-3, 5-9 and 13 do not read on the compounds disclosed in Wright, Jr., namely, 6-chloro-3-[4-(3-pyridyl)butyl]-4(3H)-quinazolinone and 6-bromo-3-[4-(3-pyridyl)butyl]-4(3H)-quinazolinone (Table 1) because n \neq 4 and X² does not include lower alkyl. Because each and every claim element is not disclosed by Wright, Jr., the claims at issue are not anticipated. Withdrawal of this rejection is respectfully requested.

CONCLUSION

Applicants respectfully assert that claims 1-14 and 16-19 are patentably distinct from the cited reference, and request that a timely Notice of Allowance be issued in this case. If there are any remaining issues preventing allowance of the pending claims that may be clarified by telephone, the Examiner is requested to call the undersigned.

Respectfully submitted,

A handwritten signature in cursive script, reading "Kevin B. Laurence", written in dark ink over a horizontal line.

Kevin B. Laurence
Reg. No. 38,219
Attorney for Applicant(s)

Date: March 15, 2007

STOEL RIVES LLP
One Utah Center
201 South Main Street, Suite 1100
Salt Lake City, UT 84111
Telephone: (801) 578-6932
Facsimile: (801) 578-6999